Form 4: Inmune Bio CFO David Moss Acquires Shares and Warrants in Direct Offering

David Moss, CFO, Treasurer, and Secretary of Inmune Bio, Inc., reports the acquisition of common stock and warrants through a registered direct offering.

Summary

• On April 19, 2024, David Moss, the CFO, Treasurer, and Secretary of Inmune Bio, Inc., acquired 18,028 shares of common stock and warrants to purchase 18,028 shares.
• The shares and warrants were purchased in a registered direct offering at a price of $8.445 per unit, totaling $152,246.46.
• Following the transaction, Moss directly owns 1,268,179 shares of Inmune Bio, Inc.
• The warrants are exercisable immediately upon issuance at an exercise price of $9.152 per share.
• The warrants expire the earlier of two years from the initial exercise date or 30 trading days following the reporting of top-line data from the Phase 2 Alzheimer's program of XPro1595, with a provision for a 60-day extension for insiders during blackout periods.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects routine insider activity. The CFO's purchase could be seen as a positive signal, but it's not overwhelmingly significant.

Positives

• The CFO's investment in the company may signal confidence in Inmune Bio's prospects.

Risks

• The warrants' expiration date is linked to the clinical trial results of XPro1595, introducing uncertainty based on the trial's outcome.

Future Outlook

The warrants' value is contingent on the success of the Phase 2 Alzheimer's program of XPro1595 and the company's stock performance.

Industry Context

Insider transactions are closely monitored as indicators of management's confidence in the company's future performance within the biotechnology industry.

Comparison to Industry Standards

• Insider buying is a common occurrence in the biotech industry, often seen as a positive signal if the insider is increasing their stake significantly.
• However, the impact on stock price depends on the size of the transaction relative to the insider's existing holdings and the company's market capitalization.
• Comparable companies like Biogen or Eli Lilly often see similar insider activity, but the market reaction varies based on the context of the company's news and performance.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive sign of confidence in the company's future prospects.

Key Dates